The Trump administration on Wednesday outlined a two-part plan aimed at creating the foundation for safely importing prescription drugs from other countries to reduce costs. "The burden is on the leadership of the Department of Health and Human Services to ensure this actually leads to lower costs for consumers — not just for insurance companies and pharmacy benefit managers — and no harm is inflicted on patients and local communities," said BIO CEO Jim Greenwood in response to the proposed plan.
Administration proposes pathway to US drug importation
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.